NCT00299936已完成3 期
Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 5,000
研究概览
简要总结
The purpose of this study is to compare PEG-interferon alfa-2b and two different doses of rivavirin for the treatment of chronic hepatitis C in previously untreated adult subjects
详细描述
Primary Objective:
This study will evaluate the safety and efficacy of two different PEG-interferon and Ribavirin regimens in patients who have not previously been treated for Hepatitis C. Patients have an equal chance to assignment to one of two treatment arms:
Treatment Arm A:
PEG-interferon 1.5 mcg/kg2 QW + Ribavirin 800 mg/day
OR
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A comparison of peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin for. postmenopausal women. with chronic hepatitis type C : An open-label randomized controlled trial.Chronic hepatitis CJPRN-UMIN000001604Hiroshima liver study group80
已完成
不适用
A comparison of peginterferon ribavirin combination therapies for chronic hepatitis CJPRN-UMIN000000897niversity of Tokyo Department of Gastroenterology, Faculty of Medicine320
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studyEUCTR2004-004736-30-ATErasmus MC122
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studychronic HBeAg-negative hepatitis BEUCTR2004-004736-30-DEFoundation of Liver research122
已完成
2 期
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)Hepatitis CHIV InfectionsNCT00008463National Institute of Allergy and Infectious Diseases (NIAID)132